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Responsible use of ﬁ xed-
dose combination 
antibiotics in India 
We value the eﬀ orts of Akram Ahmad 
and colleagues (August, 2016)1 in 
highlighting an important issue 
related to the regulation of antibiotic 
ﬁ xed-dose combination drugs (FDCs) 
in India. Moreover, we agree with 
Ahmad and colleagues that actions 
taken by the Indian Government to 
ban irrational FDCs (combinations of 
two or more active drugs in a single 
dosage form that exposes patients 
to unnecessary risk of adverse drug 
reactions) are indispensable to protect 
public health. However, certain 
questions need to be considered if 
the issue of antibiotic FDCs is to be 
addressed at the global level.
In India, 118 antibiotic FDCs are 
available, 80 (68%) of which are not 
registered with the Central Drugs 
Standard Control Organization 
(CDSCO).2 Therefore, in addition to 
placing a ban on antibiotic FDCs, 
the Indian Government must make 
sure that only evidence-based 
registered products enter the practice 
environment, and stern action 
should be taken on medicines and 
manufacturers not registered with 
CDSCO. 
Additionally, the Indian Government 
has taken a much needed step to 
restrict antibiotic resistance by 
banning irrational FDCs.1 We find it 
surprising that although a ban on 
antibiotic FDCs is imposed in India, 
there is no ban on same drugs being 
exported to African or South Asian 
Association for Regional Cooperation 
countries. Their export is deemed 
legal if the importing country has no 
objections.3 Within this context, WHO 
has approved only 350 formulations 
of FDCs to treat and prevent diseases, 
but more than 6000 combinations 
are available worldwide.3 Therefore, 
if such irrational combinations are 
exported, the eﬀ orts of other countries 
towards quality use of medicines will 
be hindered. Direct or parallel export 
of banned FDCs should be strictly 
prohibited and monitored to prevent 
irrational use or misuse of medicines 
including antibiotics.
Consequently, in addition to what 
is recommended by Ahmad and 
colleagues,1 we advise the Indian 
Government to rethink the policy 
of exporting banned FDCs and to 
monitor availability of unregistered 
products. We do agree that controlling 
antibiotic resistance in India is key 
for controlling antibiotic resistance 
worldwide; however, it does not make 
sense that strict measures could be 
taken in one region and that this 
very region could be responsible for 
promoting irrational antibiotic use 
in other areas. Antibiotic resistance is 
a global phenomenon and we need a 
global governance approach to address 
the issue.
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